Analyzing Elanco Animal Health (NYSE:ELAN) and Inhibitor Therapeutics (OTCMKTS:INTI)

Inhibitor Therapeutics (OTCMKTS:INTI – Get Free Report) and Elanco Animal Health (NYSE:ELAN – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings for Inhibitor Therapeutics and Elanco Animal Health, as provided by MarketBeat.

Get Inhibitor Therapeutics alerts:

Elanco Animal Health has a consensus target price of $28.73, indicating a potential upside of 8.72%. Given Elanco Animal Health’s stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Inhibitor Therapeutics.

Insider and Institutional Ownership

97.5% of Elanco Animal Health shares are held by institutional investors. 4.6% of Inhibitor Therapeutics shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Inhibitor Therapeutics and Elanco Animal Health”s revenue, earnings per share (EPS) and valuation.

Inhibitor Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Inhibitor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Inhibitor Therapeutics and Elanco Animal Health’s net margins, return on equity and return on assets.

Volatility and Risk

Inhibitor Therapeutics has a beta of -0.77, meaning that its share price is 177% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500.

Summary

Elanco Animal Health beats Inhibitor Therapeutics on 9 of the 14 factors compared between the two stocks.

About Inhibitor Therapeutics

(Get Free Report)

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.

About Elanco Animal Health

(Get Free Report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Receive News & Ratings for Inhibitor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibitor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.